13F Holdings
中文EN

NKTX Nkarta, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1787400 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-25.7%
TTM EPS YoY-25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-46.6%
ROA-35.1%
ROIC (approx.)-50.0%
Asset turnover—

Leverage & solvency

Liabilities / assets30.1%
Debt / equity0.00x
Current ratio5.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0———
R&D expense$90.43M$96.74M$96.77M$90.90M$63.41M
SG&A expense$31.57M$31.45M$34.88M$28.06M$23.02M
Operating income-$122.00M-$128.19M-$131.65M-$118.95M-$86.43M
Income tax$0$0$0$0$0
Net income-$104.08M-$108.79M-$117.50M-$113.84M-$86.08M
EBITDA-$112.80M-$118.99M-$125.75M-$116.36M-$84.63M
EPS (basic)-1.41-1.60-2.40-2.61-2.62
EPS (diluted)-1.41-1.60-2.40-2.61-2.62
Dividends declared per share0.000.000.00——
Weighted avg. shares (diluted)73.99M67.87M49.01M43.63M32.86M
Balance sheet
Cash & equivalents$39.63M$27.87M$31.04M$37.49M$60.82M
Short-term investments$236.65M$239.48M$217.15M$314.65M$177.27M
Current assets$282.51M$273.34M$253.07M$360.69M$245.78M
PP&E, net$66.72M$74.66M$79.33M$61.91M$12.86M
Total assets$404.21M$501.20M$378.88M$472.94M$273.90M
Current liabilities$22.27M$18.92M$23.33M$22.05M$12.94M
Total liabilities$91.88M$93.23M$105.60M$100.73M$22.94M
Shareholders' equity$312.32M$407.98M$273.29M$372.21M$250.97M
Shares outstanding71.08M70.65M49.18M48.88M32.97M
Cash flow statement
Operating cash flow-$88.70M-$99.70M-$86.16M-$57.00M-$67.93M
Capital expenditure$1.21M$4.41M$28.15M$47.11M$5.03M
Free cash flow-$89.91M-$104.11M-$114.31M-$104.11M-$72.95M
Investing cash flow$100.32M-$129.56M$79.02M-$184.69M$32.53M
Financing cash flow$141,000$226.08M$691,000$219.01M$1.20M
Depreciation & amortization$9.20M$9.20M$5.90M$2.60M$1.80M
Stock-based compensation$8.56M$16.73M$17.20M$16.86M$14.46M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.